Gururajan's research focuses on understanding the role of Fyn kinase in prostate cancer progression. Additional interests include understanding the role of noncoding RNAs and immune cells in prostate cancer. His studies have been published in several peer-reviewed publications including Blood, the Journal of Immunology and Molecular Cancer. He is a member of the American Association of Immunologists and a reviewer for several peer-reviewed medical journals. Gururajan earned his bachelor's of veterinary science (equivalent to a doctor of veterinary medicine in the United States) and master's in immunology in India. He earned his doctoral degree from the Graduate Center for Toxicology, University of Kentucky. He then completed a postdoctoral fellowship in immunology at the Emory University School of Medicine.
Lu joined the Posadas Laboratory after completing his doctor of medicine degree at National Taiwan University. He heads the research efforts of the joint Cedars-Sinai/UCLA circulating tumor cell project. The goals of his work are to study cancer evolution by serial sequencing of circulating tumor cells and to utilize this knowledge to improve cancer diagnosis and therapy. Lu is a physician scientist who is pursuing a career in translational research in oncology with the intent of combining his research and clinical interests to serve his patients.
Moldawer oversees all clinical research activities of the Urologic Oncology Program and serves as a nurse leader within the Clinical Research Office. She oversees all protocol development and clinical-translational research activites in the UOP and the Posadas Laboratory.
Oppenheim oversees clinical and translational research in prostate cancer for the Posadas Laboratory. She facilitates trail development, research pateint screening, data collection, and in collaboration with Margarit Sievert, oversees sample acquisition from clinical studies for research.
Hamann is the lead coordinator for kidney and urothlieal cancer clinical studies and oversees protocol development, patient screening, data acquisition, and in concert with Margarit Seivert, biospecimen acquisition from these studies for research.
Lichterman is the lead technologist for the circulating tumor cell project working alongside of Yi-Tsung "John" Lu, MD. He has extensive technical expertise in the use of the nanofluidic system and the analytic methods used to biologically interrogate CTCs.